TABLE C-2 Current HIV/AIDS Antiretroviral Drugs

Generic Name

Brand Name

Approval Date

Potential Side Effects

Multiclass Combination Products

Efavirenz, emtricitabine, and tenofovir disoproxil fumarate

Atripla

July 12, 2006

  • Hepatic steatosis +/–pancreatitis (severe mitochondrial toxicities)

  • Hepatotoxicity

  • Hyperlipidemia

  • Hyperpigmentation/skin discoloration

  • Lactic acidosis/Lipodystrophy

  • Nephrotoxicity

  • Osteopenia

  • Pancreatitis

  • Peripheral neuropathy

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Abacavir and lamivudine

Epzicom

August 2, 2004

  • Hypersensitivity reaction

Abacavir, zidovudine, and lamivudine

Trizivir

November 14, 2000

  • Cardiovascular effects

  • Hyperlipidemia

  • Hypersensitivity reaction

  • Lactic acidosis/hepatic steatosis +/–pancreatitis (severe mitochondrial toxicities)

  • Lipodystrophy

  • Stevens-Johnson syndrome

  • Toxic epidermal necrosis

Abacavir sulfate, ABC

Ziagen

December 17, 1998

  • Hypersensitivity reaction

  • Lipoatrophy

  • Myocardial infarctions

Didanosine, dideoxyinosine, ddI

Videx

October 9, 1991

  • Lactic acidosis

  • Pancreatitis

  • Peripheral neuropathy

Emtricitabine, FTC

Emtriva

July 2, 2003

  • Lactic acidosis

  • Lipoatrophy

Enteric-coated didanosine, ddI EC

Videx EC

October 31, 2000

  • Cardiovascular disease

  • Gastrointestinal intolerance

  • Hepatotoxicity

  • Hepatic steatosis +/–pancreatitis (severe mitochondrial toxicities)

  • Pancreatitis

  • Peripheral neuropathy

  • Stevens-Johnson syndrome

  • Toxic epidermal necrosis



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement